Screener
Nuvation Bio NUVB JP — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| United States | $23,192 | $1,238 | $100,579 | $1,238 |
| China | 7,991 | 3,354 | 13,180 | 6,254 |
| Japan | 504 | 241 | 1,156 | 425 |
| Total revenue | $31,687 | $4,833 | $114,915 | $7,917 |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's JP — revenue?
- Nuvation Bio (NUVB) reported JP — revenue of $504K in Q2 2026.
- How has Nuvation Bio's JP — revenue changed year-over-year?
- Nuvation Bio's JP — revenue increased by 109.1% year-over-year, from $241K to $504K.
- What does JP — revenue mean?
- This metric represents the total gross income generated by the company from its operations within the Japan geographic segment. It reflects the company's ability to monetize its therapeutic candidates and commercial activities in this specific market. Tracking this figure helps investors assess the geographic diversification of the company's revenue streams and the adoption rate of its oncology portfolio in the Japanese market.
Ask your AI about Nuvation Bio's jp — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude